Opicapone versus placebo in the treatment of Parkinson’s disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial

BACKGROUND: Optimisation of dopaminergic therapy may alleviate fluctuation-related pain in Parkinson’s disease (PD). Opicapone (OPC) is a third-generation, once-daily catechol-O-methyltransferase inhibitor shown to be generally well tolerated and efficacious in reducing OFF-time in two pivotal trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaudhuri, K. Ray, Odin, Per, Ferreira, Joaquim J., Antonini, Angelo, Rascol, Olivier, Kurtis, Mónica M., Storch, Alexander, Bannister, Kirsty, Soares-da-Silva, Patrício, Costa, Raquel, Magalhães, Diogo, Rocha, José Francisco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917369/
https://www.ncbi.nlm.nih.gov/pubmed/35279112
http://dx.doi.org/10.1186/s12883-022-02602-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917369/
https://www.ncbi.nlm.nih.gov/pubmed/35279112
http://dx.doi.org/10.1186/s12883-022-02602-8

Ejemplares similares